Compare COGT & WH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | WH |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.7B |
| IPO Year | 2018 | N/A |
| Metric | COGT | WH |
|---|---|---|
| Price | $39.91 | $78.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $32.08 | ★ $94.04 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 02-24-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 2.06% |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ 4.33 |
| Revenue | N/A | ★ $1,436,000,000.00 |
| Revenue This Year | N/A | $5.20 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | ★ N/A | $18.36 |
| Revenue Growth | N/A | ★ 3.83 |
| 52 Week Low | $3.72 | $69.21 |
| 52 Week High | $43.73 | $113.07 |
| Indicator | COGT | WH |
|---|---|---|
| Relative Strength Index (RSI) | 62.18 | 53.48 |
| Support Level | $37.70 | $77.24 |
| Resistance Level | $40.40 | $81.48 |
| Average True Range (ATR) | 1.89 | 2.52 |
| MACD | 0.31 | -0.11 |
| Stochastic Oscillator | 83.91 | 67.14 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
As of June 30, 2025, Wyndham Hotels & Resorts operates 846,700 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands, as of the end of 2024. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms, as of the end of 2024.